Kancera AB (publ) reports that 63 subjects have been recruited to the ongoing FRACTAL-study, a phase IIa study of KAND567 in myocardial infarction patients, which exceeds the initial objective of 60 study subjects in total. Kancera has previously announced the decision to amend the study protocol to allow for recruitment of up to 70 study subjects in total, in order to strengthen the study in terms of number of evaluable subjects. Kancera now announces that the recruitment period is extended, to the end of February 2023 at the latest, as the objective to report top line data during Q3 2023 can still be met.
Enrollment of study subjects has progressed well throughout 2022 and, as of today, 63 subjects in total have been recruited. This exceeds the initial objective of 60 study subjects in total. In order to strengthen the study in terms of number of evaluable subjects, Kancera and NHS Foundation decided in September 2022 to amend the study protocol to allow for enrollment of up to 70 study subjects in total. The expectation was that recruitment of 70 subjects would be completed by January 2023, but the company now announces that the recruitment period is extended to the end of February, at the latest. Kancera believes that this extension is well motivated, as the objective to report top line results in Q3 2023 can still be met, and an extension is made to allow for a maximum number of evaluable subjects, which strengthens the study.
The FRACTAL-study is a phase IIa clinical study of KAND567 in myocardial infarction patients undergoing percutaneous coronary intervention. The study is conducted in collaboration with the British NHS Foundation, which is the sponsor of the study. The FRACTAL-study is conducted at the Freeman Hospital in Newcastle and James Cook Hospital in Middlesbrough. The primary objective of the study is to evaluate safety and tolerability. The secondary objective is to evaluate evidence of KAND567’s treatment efficacy.
About Kancera AB (publ)
Kancera is developing a new class of drugs for treatment of cancer and severe inflammatory diseases, that today are lacking effective treatments. Kancera’s main focus is to develop small molecule drug candidates based on the Fractalkine system. Fractalkine is a natural master regulator that with precision controls immune cells and cancer cells. The stock is traded on the Nasdaq First North Premier Growth Market. FNCA Sweden AB (info@fnca.se) is the company's Certified Adviser.
For further information:
Thomas Olin
Chief Executive Officer, Kancera AB
Tel: +46-73-620 40 01
Visit Kancera’s web page: https://www.kancera.com/en
KANCERA AB 
